Gene panels such as the HAMP–FTH1–SLC11A2 axis show potential as biomarkers for high-risk, inflammation-driven CRC; however, they require large-scale validation in prospective longitudinal cohorts before clinical implementation. Here, FTH1 is linked to colorectal carcinoma.